PubMed Health⌕ Search

Biomedical subjects

C Susini

Publications and source records attributed to C Susini.

81 records · Page 5Linked to original sources

[U-14C]glucose metabolism in vivo in rats rendered obese by a high fat diet.

Estimates of the glucose pool, the glucose space, the turnover rate, and the recycling of glucose were made after the injection of [U-14C]glucose into (a) obese rats fed a high fat diet and (b) rats fed a carbohydrate diet. The specific activity--time curve consisted of two components. Physiological parameters were calculated by using a two-compartment model. The glucose pool and glucose space were the same in both groups of rats. The turnover rate was 1.96 mg. min-1 for the carbohydrate-fed rats and 1.55 mg. min-1 for the fat-fed rats. There was about 12 percent recycling in both groups. In the carbohydrate-fed group, another approach based on simultaneous use of [6-14C]glucose and [6-3H]glucose yielded nearly the same values for these parameters. Respiratory excretion of CO2 and the incorporation of labeled glucose into lipids of some tissues were also measured. The rate of excretion of labeled CO2 and the conversion of labeled glucose into fatty acids in fat-fed rats were lower than in the carbohydrate-fed rats by 50 percent and 80 percent, respectively. More glucose was diverted into glyceride glycerol in the fat-fed group. It is suggested on the basis of the results that glyceride glycerol can serve as a gluconeogenic substrate in these rats where the turnover rate of glucose is much higher than the daily intake of carbohydrates.

Adipose Tissue↗

Somatostatin analogs: correlation of receptor affinity with inhibition of cyclic AMP formation in pancreatic acinar cells.

Somatostatin inhibited secretin-stimulated cyclic AMP formation in pancreatic acinar cells. The inhibition was only partial. Maximal inhibition reached about 50%. Somatostatin analogs tested inhibited secretin-stimulated cyclic AMP formation with a lower potency than somatostatin. Cys-Aza Ala-Phe-Phe-DTrp-Lys-Thr-Phe-Phe-Cys was found to be an antagonist of somatostatin in inhibiting secretin-stimulated cyclic AMP. Analogs inhibited the binding of 125I-[Tyr11] somatostatin to pancreatic acini. There was a good correlation (r = 0.97) between concentration for inhibiting 50% secretin-stimulated cyclic AMP and receptor binding affinities.

Amino Acid Sequence↗

Calcium-dependence of somatostatin binding to receptors.

Binding of 125I-[Tyr11] somatostatin (S14) and 125I-[Tyr1]S14 has been studied in pancreatic acini and cerebral cortex. Ca2+-dependence of somatostatin binding to receptors was observed only with the highly non degradable iodinated analog 125I-[Tyr11] somatostatin but not with 125I-[Tyr1] somatostatin. The inhibitory activity of S14 on secretin-stimulated cAMP cellular content was decreased when Ca2+ concentration in the medium was reduced to 30 nM, indicating that the Ca2+ dependence of somatostatin binding to receptors is also present with the native peptide.

Animals↗

Characterization of pancreatic somatostatin binding sites with a 125I-somatostatin 28 analog.

Somatostatin binding to guinea pig pancreatic acinar cell plasma membranes was characterized with an iodinated stable analog of somatostatin 28 (S28): 125I-[Leu8,DTrp22,Tyr25]S28. The binding was highly dependent on calcium ions. In 0.2 mM free Ca2+ medium, binding at 37 degrees C was saturable, slowly reversible and exhibited a single class of high affinity binding sites (KD = 0.05 +/- 0.01 nM, Bmax = 157 +/- 33 fmol/mg protein). Dissociation of bound radioactivity occurred with biphasic kinetics. Rate of dissociation increased when dissociation was measured at a time before equilibrium binding was reached. In 30 nM free Ca2+ medium, binding affinity and maximal binding capacity were decreased by about 4-fold. Decreasing calcium concentrations increased the amount of rapidly dissociating form of the receptor. Somatostatin 14 antagonist, Des AA1,2[AzaAla4-5,DTrp8, Phe12-13]-somatostatin was active at the membrane level in inhibiting the binding. We conclude that using 125I-[Leu8,DTrp22,Tyr25]S28 as radioligand allows us to characterize a population of specific somatostatin receptors which are not different from those we previously described with the radioligand 125I-[Tyr11]-somatostatin. Somatostatin receptors could exist in two interconvertible forms. Calcium ions are an essential component in the regulation of the conformational change of somatostatin receptors.

Animals↗

Interactions between neuropeptides and dexamethasone on the mitogenic response of rabbit spleen lymphocytes.

The interactions between vasoactive intestinal peptide (VIP), substance P (SP), a somatostatin analog (SMS 201-995) and dexamethasone have been investigated on the Con A mitogenic response of rabbit spleen cells. The neuropeptide regulatory effects appeared to be time dependent: when added with the Con A mitogen, they inhibited (VIP) or did not modulate (SMS and SP) the rabbit lymphocyte proliferation and did not change the inhibitory effect induced by a dexamethasone preincubation. When added 18 h before the mitogen, they all induced an increase of the proliferative response at high concentration. The mitogenic response observed when adding dexamethasone to lymphocytes previously preincubated in the presence of neuropeptides was not different from control response except with SMS 10(-10) M. The similar lymphocyte responses obtained whatever the neuropeptide suggested that the immunomodulatory effect induced by a neuropeptide preincubation might be mediated by the induction of common effector(s).

Animals↗

Signal transduction of somatostatin receptors negatively controlling cell proliferation.

Somatostatin acts as an inhibitory peptide of various secretory and proliferative responses. Its effects are mediated by a family of G-protein-coupled receptors (sst1-5) that can couple to diverse signal transduction pathways such as inhibition of adenylate cyclase and guanylate cyclase, modulation of ionic conductance channels, and protein dephosphorylation. The five receptors bind the natural peptide with high affinity but only sst2, sst5 and sst3 bind the short synthetic analogues. Somatostatin negatively regulates the growth of various normal and tumour cells. This effect is mediated indirectly through inhibition of secretion of growth-promoting factors, angiogenesis and modulation of the immune system. Somatostatin can also act directly through sst receptors present on target cells. The five receptors are expressed in various normal and tumour cells, the expression of each receptor being receptor subtype and cell type specific. According to the receptor subtypes, distinct signal transduction pathways are involved in the antiproliferative action of somatostatin. Sst1, 4 and 5 modulate the MAP kinase pathway and induce G1 cell cycle arrest. Sst3 and sst2 promote apoptosis by p53-dependent and -independent mechanisms, respectively.

Animals↗